Blockchain Registration Transaction Record

Annovis Bio Activates All 84 Sites for Alzheimer's Phase 3 Trial

Annovis Bio announces all 84 U.S. sites for its Phase 3 Alzheimer's trial are now active and enrolling patients, with data expected in 2026 for experimental drug buntanetap.

This development represents significant progress in the fight against Alzheimer's disease, a condition affecting over 6 million Americans and millions more worldwide. The successful activation of all trial sites and continued patient enrollment brings hope for a potential new treatment option in a field where effective therapies remain limited. For patients and families affected by Alzheimer's, this advancement could mean access to a novel therapy that addresses the underlying neurodegeneration rather than just managing symptoms. The progress also signals important momentum in neurodegenerative disease research, potentially paving the way for similar approaches to treat other conditions like Parkinson's disease. With Alzheimer's being one of the most costly and devastating diseases for healthcare systems and families, any advancement in treatment development carries substantial implications for public health and quality of life for aging populations.